| Literature DB >> 16679089 |
Masoor Kamalesh1, Roopa Rao, Stephen Sawada, Amy Friend, Ellen Schellhase, Tamara Evans.
Abstract
It is not known whether high-dose statins can reduce the excess burden (and consequent adverse cardiovascular outcomes) of coronary artery disease in patients with metabolic syndrome compared with those without metabolic syndrome. The results of our study suggest that high-dose simvastatin may be required to reduce excess events in very high-risk cohorts with metabolic syndrome.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16679089 DOI： 10.1016/j.amjcard.2005.11.083
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778